Skip to main content

Analysts’ Top Healthcare Picks: Harrow Health (HROW), Ardelyx (ARDX)

Tipranks - Tipranks - Tue Nov 11, 2025

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Harrow Health (HROW – Research Report), Ardelyx (ARDX – Research Report) and 908 Devices (MASS – Research Report) with bullish sentiments.

Meet Your ETF AI Analyst

Harrow Health (HROW)

In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Harrow Health. The company’s shares closed last Monday at $35.00.

According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of 34.6% and a 62.2% success rate. Knickerbocker covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Xtant Medical Holdings, and Diamedica Therapeutics. ;'>

Currently, the analyst consensus on Harrow Health is a Strong Buy with an average price target of $67.75.

See today’s best-performing stocks on TipRanks >>

Ardelyx (ARDX)

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Ardelyx, with a price target of $14.00. The company’s shares closed last Monday at $5.69.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 32.3% and a 54.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Mereo Biopharma Group Plc. ;'>

Currently, the analyst consensus on Ardelyx is a Strong Buy with an average price target of $11.50, representing a 103.9% upside. In a report issued on October 31, TD Cowen also maintained a Buy rating on the stock with a $10.00 price target.

908 Devices (MASS)

William Blair analyst Matt Larew maintained a Buy rating on 908 Devices today. The company’s shares closed last Monday at $6.78, close to its 52-week high of $7.56.

According to TipRanks.com, Larew is a 1-star analyst with an average return of -0.9% and a 47.9% success rate. Larew covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, West Pharmaceutical Services, and Ginkgo Bioworks Holdings. ;'>

908 Devices has an analyst consensus of Moderate Buy.

Read More on HROW:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).